Drugs / fecal microbial transplantation
fecal microbial transplantation
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04951583 | Nov 2021 → Sep 2024 overdue | melanoma, non-small cell lung carcinoma | University of Montreal Hospital Centre (CHUM) | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fecal microbial transplantation | “combination with fecal microbial transplantation (FMT)” NCT04951583 ↗ |
| Known as | fecal microbiota transplantation | “Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial.” PMID 41606121 ↗ Jan 2026 |
| Known as | FMT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04951583 ↗ |
| Route | Oral | “Eligible patients received a single FMT via oral capsules prior to ICI initiation.” PMID 41606121 ↗ Jan 2026 |